Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma

Translational data combines advanced artificial intelligence (AI), immunogenomics, histopathology, and spatial transcriptomics to provide mechanistic insights into therapeutic response and disease progression

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies